Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:publications:blaney_autoimmunity_2010 [06.09.2010] joyfulhome:publications:blaney_autoimmunity_2010 [06.14.2010] paulalbert
Line 13: Line 13:
 **Date:**  May 2010\\ **Date:**  May 2010\\
  
 +===== Abstract =====
 +
 +
 +Recent research highlights the importance of VDR integrity and responsiveness on innate immune function. VDR knock out mice show both an increased frequency and severity of autoimmune disease and reduced ability to cope with bacterial infection and persistence. We have found that autoimmune disease in humans is associated with elevated levels of 1,25 OH Vitamin D indicating VDR resistance. Co-morbid conditions such as colitis, sinusitis, vasculitis and recurrent infections, reflecting intracellular or biofilm bacterial persistence, have been found by ourselves and others in autoimmune diseases. In silico modeling and clinical observation show that olmesartan medoxomil, an angiotensin receptor blocker, acts as a VDR agonist. Selected patients with significant and advanced autoimmune disease, including inflammatory arthropathy, autoimmune thyroiditis, ankylosing spondylitis, sarcoidosis,  were treated with olmesartan at dosing levels sufficient to activate the VDR along with bacteriostatic antibiotics at sub-inhibitory dose levels. During treatment, temporary exacerbation of symptoms and worsening of clinical markers were seen reflecting immune response. Physical manifestations included inflammation and swelling of joints, dermatitis, central and peripheral nervous system dysfunction, fever and fatigue. Laboratory changes included reduction in red and white blood cells, platelets; elevation in serum potassium, creatinine; and reduction in eGFR. After sufficient time of treatment, positive therapeutic responses that manifested included reversal of late-stage autoimmune conditions including carotid artery calcification, inflammatory joint disease, neuropathy, and osteoporosis. In addition normalization of clinical markers such as CRP,SED rate, kidney function were observed.  
  
 ===== Transcript ===== ===== Transcript =====
home/publications/blaney_autoimmunity_2010.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.